Despite the promising observations with PD-1 blockade in advanced NSCLC, cancer immunotherapy triggers an efficient T-lymphocyte mediated immune surveillance in a minority of patients.5 In certain circumstances that still remain poorly understood, a rapid progression is occasionally observed, reinforcing the urgent need to identify ways to efficiently circumvent resistance to ICI. The gene discussed is PDCD1; the disease is cancer.